Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
03.10. | EXOZYMES INC. - 8-K, Current Report | 2 | SEC Filings | ||
30.09. | Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees | 230 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
12.08. | eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today | 324 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered... ► Artikel lesen | |
12.08. | EXOZYMES INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
08.08. | eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST | 309 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
EXOZYMES Aktie jetzt für 0€ handeln | |||||
29.07. | eXoZymes achieves 99% purity in lab-scale NCT production | 1 | Investing.com | ||
29.07. | eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity | 414 | ACCESS Newswire | Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.NCT project went from concept to... ► Artikel lesen | |
22.07. | eXoZymes meldet Durchbruch bei Bioproduktion von NCT | 3 | Investing.com Deutsch | ||
22.07. | eXoZymes achieves breakthrough in NCT biomanufacturing process | 2 | Investing.com | ||
22.07. | eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months | 451 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial... ► Artikel lesen | |
07.07. | Hedge Fund and Insider Trading News: Bill Ackman, Michael Platt, Scott Bessent, Point72 Asset Management, Berkshire Hathaway, Lakehouse Capital, Exozymes Inc (EXOZ), and More | 38 | Insider Monkey | ||
26.06. | eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing | 370 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines... ► Artikel lesen | |
20.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
16.05. | eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast | 462 | ACCESS Newswire | MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
13.05. | eXoZymes reports Q1 results | 2 | Seeking Alpha | ||
12.05. | eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today | 312 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that... ► Artikel lesen | |
12.05. | EXOZYMES INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
07.05. | eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST | 409 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines,... ► Artikel lesen | |
06.05. | eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health | 309 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier... ► Artikel lesen | |
25.04. | EXOZYMES INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PRAXIS PRECISION MEDICINES | 189,99 | +16,77 % | Praxis Precision Medicines prices $525M public offering | ||
QIAGEN | 41,345 | +0,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
RANI THERAPEUTICS | 1,640 | +248,20 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
NUVALENT | 92,52 | +2,32 % | Stifel initiates coverage on Nuvalent stock with Buy rating | ||
RECURSION PHARMACEUTICALS | 5,860 | -7,86 % | Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event | ||
KYMERA THERAPEUTICS | 59,83 | -1,11 % | The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts | ||
IMMUNOVANT | 17,510 | +0,57 % | Truist Securities initiates Immunovant stock with Hold rating, $16 target | ||
COGENT BIOSCIENCES | 16,390 | +0,18 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
TREVI THERAPEUTICS | 10,360 | -2,45 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
ARTIVA BIOTHERAPEUTICS | 6,020 | +118,12 % | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen | |
SANA BIOTECHNOLOGY | 5,030 | -5,18 % | Sana Biotech surges as Eric Jackson calls it a 100-bagger | ||
IMMUNOME | 15,670 | -5,03 % | Where Immunome Stands With Analysts | ||
ARVINAS | 9,520 | -1,60 % | Forecasting The Future: 7 Analyst Projections For Arvinas | ||
AMYLYX PHARMACEUTICALS | 14,950 | -1,45 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
DISC MEDICINE | 89,90 | +20,90 % | Disc Medicine Inc: Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPPThe CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN,... ► Artikel lesen |